Vasopressin

Hypersensitivity to vasopressin and chlorobutanol. Coronary artery disease, chronic nephritis with nitrogen retention.

Patient with CV disease, vascular disease, heart failure, migraine, asthma, or epilepsy. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor serum and urine Na, urine and serum osmolality, urine specific gravity, urine output, fluid input and output, blood pressure, heart rate and digital or extremity perfusion during therapy. Monitor electrolytes, fluid status, and urine output after vasopressin discontinuation. Monitor BUN levels in patients with chronic nephritis.

Significant: Reversible diabetes insipidus (following discontinuation of treatment), water intoxication; extravasation; decreased cardiac output. Blood and lymphatic system disorders: Decreased platelet count, intractable bleeding. Cardiac disorders: Angina, cardiac arrest, atrial fibrillation, bradycardia, myocardial ischaemia, right heart failure. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, flatulence, abdominal pain, mesenteric ischaemia. General disorders and administration site conditions: Non-cardiac chest pain. Immune system disorders: Hypersensitivity, anaphylaxis. Investigations: Increased serum bilirubin. Metabolism and nutrition disorders: Hyponatraemia. Nervous system disorders: Headache, vertigo, tremor. Renal and urinary disorders: Fluid retention, acute renal insufficiency. Respiratory, thoracic and mediastinal disorders: Bronchospasm. Skin and subcutaneous tissue disorders: Gangrene, hyperhidrosis, urticaria, ischaemic lesions. Vascular disorders: Hypertension, pallor, peripheral ischaemia, haemorrhagic shock.

Enhanced therapeutic effect with indometacin specifically on cardiac index and systemic vascular resistance. Enhanced effect on mean arterial blood pressure with ganglionic blocking agents (e.g. mecamylamine). Increased pressor and antidiuretic effects with drugs suspected of causing SIADH (e.g. TCAs, SSRIs, carbamazepine, haloperidol, chlorpropamide, methyldopa, enalapril, clofibrate, fludrocortisone, urea, pentamidine, ifosfamide, cyclophosphamide, vincristine, felbamate). Decreased pressor and antidiuretic effects with drugs suspected of causing diabetes insipidus (e.g. clozapine, lithium, foscarnet, demeclocycline, heparin, alcohol, norepinephrine).

Antidiuretics / Haemostatics